MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
0.5601
-0.0119
-2.08%
After Hours: 0.5603 +0.0002 +0.04% 19:48 07/02 EDT
OPEN
0.5700
PREV CLOSE
0.5720
HIGH
0.6001
LOW
0.5600
VOLUME
49.03K
TURNOVER
--
52 WEEK HIGH
1.550
52 WEEK LOW
0.4600
MARKET CAP
13.88M
P/E (TTM)
-1.1700
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LEXX last week (0622-0626)?
Weekly Report · 4d ago
Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing
TipRanks · 06/25 13:15
Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy
Benzinga · 06/25 13:14
Lexaria begins dosing in five-week oral semaglutide study versus Novo’s Wegovy tablets
PUBT · 06/25 13:10
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Barchart · 06/25 08:10
Lexaria Bioscience begins dosing in animal study GLP-1-A26-1
TipRanks · 06/23 15:26
Lexaria receives Australian patent grant for hypertension treatment compositions
PUBT · 06/23 13:25
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Barchart · 06/23 08:25
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Webull offers Lexaria Bioscience Corp stock information, including NASDAQ: LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.